Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

Multi-center, open-label study that will compare the onset of the platelet inhibition with
ticagrelor versus clopidogrel when administered with bivalirudin during PCI on a background
therapy of aspirin in patients with NSTE-ACS.

Inclusion Criteria:

- Hospitalised for chest pain and potential acute coronary syndrome.

- Onset of the most recent cardiac ischemic symptoms must occur within 7 days before
randomisation and documented by cardiac ischemic symptoms of ≥ 10 min duration at
rest and at least 2 of the following: ST segment changes on ECG indicative of
ischemia, or Positive biomarker evdience of myocardial necrosis, or other risk
factors such as: 60 yrs of age or older, previous myocardial infarction or coronary
bypass surgery, multi-vessel coronary artery disease, diabetes mellitus, peripheral
arterial disease, chronic renal disfunction.

- Females must be either surgically sterile or post-menopausal.

- ACT
Exclusion Criteria:

- Participation in another clinical study with an investigational product during the
last 30 days.

- Current acute complication of percutaneous coronary intervention or coronary bypass
surgery.

- Any contraindication to ticagrelor, clopidogrel or bivalirudin.

- ST elevation myocardial infraction within 24 hours of study entry.

- Any indications for oral anticoagulation or aspirin dose other than 75 to 100 mg
daily.

- Planned use of omeprazole or esomeprazole.

- Patients with known bleeding or coagulation disorders; patients requiring dialysis;
patients who have an inability to swallow medication.

- Patients with known bleeding diathesis or coagulation disorder; history of
intracranial bleed.

- Use of IV heparin less than 2 hours before procedure.

- Sustained uncontrolled high blood pressure